Brief cold water or cold air. Best supported: less muscle soreness and better perceived recovery after hard exercise, plus a large but temporary rise in heat production. Calmer feelings and better sleep are less certain; blood sugar and insulin are largely unchanged. Costs: the involuntary gasp behind most cold-water drownings, and less muscle built when cooling follows lifting. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting blood pressure | Below 120/80 mmHg | Cold raises pressure sharply; a high baseline widens the acute surge |
| Resting heart rate and heart rate variability | Resting heart rate 50–65 bpm; heart rate variability stable or rising against the individual's own 30-day baseline | Distinguishes an absorbed cold load from accumulating strain |
| Fasting glucose | 75–90 mg/dL (4.2–5.0 mmol/L) | Establishes glucose control before testing whether cold acclimation improves it |
| HbA1c | 4.8–5.4% | Three-month blood-glucose control, the endpoint cold acclimation would plausibly move |
| Fasting insulin and HOMA-IR | Insulin 2–5 µIU/mL; HOMA-IR below 1.0 | Captures the insulin-sensitivity signal reported in cold-acclimation trials |
| hs-CRP | Below 0.5 mg/L | Cold raises inflammation acutely; a rising trend signals inadequate recovery |
| Thyroid panel | TSH 0.5–2.0 mIU/L; free T3 in the upper third of the laboratory reference range | Thyroid output sets baseline heat production; low output magnifies cold intolerance |
| Resting 12-lead electrocardiogram | No established numeric target — a normal trace with no pre-excitation, blocked electrical conduction or prolonged QT interval | Screens for the rhythm faults that make competing nerve signals dangerous |
| Lean body mass | No established target — track change from the individual's own baseline | Detects whether post-training cooling is costing muscle |
Cadence: Baseline panel before starting; blood pressure and heart rate variability weekly through the first month while exposures are escalating; metabolic and inflammatory markers rechecked at 12 weeks; review every 6–12 months once the protocol is stable.